UPDATE: Aegis Capital Downgrades Galectin Therapeutics

By: via Benzinga
In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.